Abstract
A lthough current drug protocols used to prevent organ rejection in transplant recipients have been highly successful, recipients must take anti-rejection drugs for the rest of their lives and endure risk of opportunistic infections and lymphoproliferative disorders. An alternative strategy would be to induce donor-specific tolerance using a short term protocol. We have previously demonstrated that a single donor-specific blood transfusion (DST) combined with a short course of cyclosporine A (CsA) significantly prolongs the survival of cardiac allografts in the high responding AC1 to Lewis rat model.’ The addition of a third agent, such as rapamycin, IL-4 or nutritional therapy to this protocol produces long-term tolerance in a significant number of recipients.2-4 Overly aggressive immunosuppression in this model does not improve allograft survival and in some cases decreases it.5 The mechanisms responsible for these observations are not completely understood. Recent studies of cytokine profiles associated with allograft rejection and tolerance induction suggest the ThUTh2, Tcl/Tc2 paradigm as a mechanism of tolerance with a Th2 phenotype being associated with tolerance and a Thl phenotype closely linked to rejection.‘j In order to elucidate the possible role played by these cell types and cytokines, we monitored the production of IL-4 and INF-y from CD3+CD4’ and CD3’CD8+ lymphocytes in an AC1 to Lewis rat allograft model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.